

## **PainChek® granted Australian patent for pain assessment invention**

**May 8<sup>th</sup> 2020:** Listed Australian company PainChek® (ASX:PCK) announced today the Australian Patent Office has issued a Notice of Allowance for its pain assessment invention.

The Notice of the acceptance will appear in the Australian Official Journal of Patents on 14 May 2020 and confirms the patent prosecution has been successfully completed.

The patent allows PainChek® to protect the intellectual property of its invention in Australia, provides a platform for growing the brand in international markets and gives PainChek® exclusive rights to exclude others from making, using, selling or importing the invention until 18<sup>th</sup> August 2035 which is 20 years from the completed filing date in the Australia.

PainChek® is the world's first smartphone pain assessment and monitoring device. The app automatically assesses pain via artificial intelligence and facial recognition technology. Research<sup>1</sup> shows it is already driving higher quality aged care and improved pain management in residential settings around Australia.

According to Philip Daffas, PainChek® CEO, the patent is the latest in a series of growth milestones for the company. "After working on this application since early 2017, we now have accepted patents for PainChek® technology in USA, Japan and now in our home market Australia. We are awaiting further approvals in other markets including Europe, United Kingdom and China" said Daffas.

The announcement comes as PainChek has recently submitted the FDA De-Novo pre-sub supplement to the FDA which provides a regulatory pathway for PainChek® to market the adult version App in the US (see ASX release dated 14 April 2020). The ongoing De Novo application confirms PainChek® is a first in kind from a US regulatory standpoint and the granting of the US patent confirms that we are first in kind from an intellectual property standpoint.

"From a business perspective, the US, Japan and Australia are cornerstone markets for our global strategy and where there are more than ten Million people living with dementia<sup>2</sup>. Establishing our intellectual property in these markets is a crucial step forward as part of protecting and growing the PainChek® brand internationally," added Daffas.

This ASX announcement has been approved for release by Philip Daffas, Managing Director.

### **For more information:**

Ian Hobson Company Secretary, PainChek <a href="mailto:ianhobson@bigpond.com">ianhobson@bigpond.com</a> +61 8 9388 8290	Philip Daffas CEO, PainChek <a href="mailto:philip.daffas@painchek.com">philip.daffas@painchek.com</a> 0406 537 235
--	--

<sup>1</sup> Clinical Studies' PainChek 2019, <https://www.painchek.com/clinical-studies/>

<sup>2</sup> [www.alz.co.uk/sites/default/files/conf2018/3\\_DY\\_Suharya\\_Asia\\_Pacific\\_response\\_to\\_global\\_action\\_plan\\_on\\_dementia.pdf](http://www.alz.co.uk/sites/default/files/conf2018/3_DY_Suharya_Asia_Pacific_response_to_global_action_plan_on_dementia.pdf)

### About PainChek®

PainChek® Ltd is an Australian based company that develops pain assessment technologies.


PainChek® is a smart-phone based medical device using artificial intelligence to assess and score pain levels in real time and update medical records in the cloud. PainChek® records a short video of the person's face and analyses the images that indicate pain and records them.

Next, the caregiver uses PainChek® to record their observations of other pain related behaviours that complete the assessment. Finally, PainChek® calculates an overall pain score and stores the result allowing the caregiver to monitor the effect of medication and treatment over time.


PainChek® is being rolled out globally in two phases: first, PainChek® for adults who are unable to effectively verbalise their pain such as people with dementia, and second, PainChek® for Children who have not yet learnt to speak.

The PainChek® Shared Care Program is a PainChek® licensing model which enables a professional carer to share their resident or patient data securely with other healthcare professionals or designated homebased family carers for ongoing pain assessments or clinical data review.

To find out more, visit [www.painchek.com](http://www.painchek.com)



PainChek® artificial intelligence assesses facial micro-expressions that are indicative of the presence of pain.



PainChek® domains of pain assessment that calculates pain severity score.